246 related articles for article (PubMed ID: 17350467)
21. Isodicentric Philadelphia chromosomes in imatinib mesylate (Gleevec)-resistant patients.
Szych CM; Liesveld JL; Iqbal MA; Li L; Siebert S; Asmus C; O'Malley J; Lee A; Wang N
Cancer Genet Cytogenet; 2007 Apr; 174(2):132-7. PubMed ID: 17452255
[TBL] [Abstract][Full Text] [Related]
22. Chronic myelogenous leukemia with the e6a2 BCR-ABL and lacking imatinib response: presentation of two cases.
Vefring HK; Gruber FX; Wee L; Hovland R; Hjorth-Hansen H; Gedde Dahl T; Meyer P
Acta Haematol; 2009; 122(1):11-6. PubMed ID: 19641300
[TBL] [Abstract][Full Text] [Related]
23. Novel variant Ph translocation t(9;22;11)(q34;q11.2;p15)inv(9)(p13q34) in chronic myeloid leukemia involving a one-step mechanism.
Belli C; Alú MF; Alfonso G; Bianchini M; Larripa I
Cytogenet Genome Res; 2011; 132(4):304-8. PubMed ID: 21212648
[TBL] [Abstract][Full Text] [Related]
24. Promyelocytic crisis of chronic myelogenous leukaemia during imatinib mesylate treatment.
Oku E; Imamura R; Nagata S; Takata Y; Seki R; Otsubo K; Hashiguchi M; Osaki K; Yakushiji K; Yoshimoto K; Ogata H; Sata M; Okamura T
Acta Haematol; 2007; 117(4):191-6. PubMed ID: 17170522
[TBL] [Abstract][Full Text] [Related]
25. Imatinib mesylate efficacy in 72 previously treated Philadelphia-positive chronic myeloid leukemia patients with and without additional chromosomal changes: single-center results.
Holzerová M; Faber E; Veselovská J; Urbánková H; Balcárková J; Rozmanová S; Voglová J; Muzík J; Chroust K; Indrák K; Jarosová M;
Cancer Genet Cytogenet; 2009 May; 191(1):1-9. PubMed ID: 19389502
[TBL] [Abstract][Full Text] [Related]
26. [Disappearance of a Philadelphia chromosome-positive clone and appearance of a -negative clone following treatment with imatinib mesylate in acute myelomonocytic leukemia].
Takahashi W; Arai Y; Tadokoro J; Takeuchi K; Yamagata T; Mitani K
Rinsho Ketsueki; 2006 Feb; 47(2):111-4. PubMed ID: 16529013
[TBL] [Abstract][Full Text] [Related]
27. Simultaneous occurrence of t(9;22)(q34;q11.2) and t(16;16)(p13;q22) in a patient with chronic myeloid leukemia in blastic phase.
Zámecníkova A; Al Bahar S; Ramesh P
Cancer Genet Cytogenet; 2008 Jun; 183(2):109-13. PubMed ID: 18503829
[TBL] [Abstract][Full Text] [Related]
28. Chromosome abnormalities additional to the Philadelphia chromosome at the diagnosis of chronic myelogenous leukemia: pathogenetic and prognostic implications.
Zaccaria A; Testoni N; Valenti AM; Luatti S; Tonelli M; Marzocchi G; Cipriani R; Baldazzi C; Giannini B; Stacchini M; Gamberini C; Castagnetti F; Rosti G; Azzena A; Cavazzini F; Cianciulli AM; Dalsass A; Donti E; Giugliano E; Gozzetti A; Grimoldi MG; Ronconi S; Santoro A; Spedicato F; Zanatta L; Baccarani M;
Cancer Genet Cytogenet; 2010 Jun; 199(2):76-80. PubMed ID: 20471509
[TBL] [Abstract][Full Text] [Related]
29. A 2-year-old with atypical CML with a t(5;12)(q33;p13) treated successfully with imatinib mesylate.
Wittman B; Horan J; Baxter J; Goldberg J; Felgar R; Baylor E; Cromwell B; Cross N; Bennett JM
Leuk Res; 2004 May; 28 Suppl 1():S65-9. PubMed ID: 15036944
[TBL] [Abstract][Full Text] [Related]
30. Clonal Ph-negative hematopoiesis in CML after therapy with imatinib mesylate is frequently characterized by trisomy 8.
Andersen MK; Pedersen-Bjergaard J; Kjeldsen L; Dufva IH; Brøndum-Nielsen K
Leukemia; 2002 Jul; 16(7):1390-3. PubMed ID: 12094265
[No Abstract] [Full Text] [Related]
31. CML clonal evolution with resistance to single agent imatinib therapy.
Swords R; Quinn J; Fay M; O'Donnell R; Goldman J; Murphy PT
Clin Lab Haematol; 2005 Oct; 27(5):347-9. PubMed ID: 16178920
[TBL] [Abstract][Full Text] [Related]
32. Sustained, clonal karyotype abnormalities in the Philadelphia chromosome negative cells of CML patients successfully treated with Imatinib.
Meeus P; Demuynck H; Martiat P; Michaux L; Wouters E; Hagemeijer A
Leukemia; 2003 Feb; 17(2):465-7. PubMed ID: 12592350
[No Abstract] [Full Text] [Related]
33. Addition of sargramostim (GM-CSF) to imatinib results in major cytogenetic response in a patient with chronic myeloid leukemia.
Connor RF; Hurd D; Pettenati MJ; Koty P; Molnár I
Leuk Res; 2006 Oct; 30(10):1249-52. PubMed ID: 16580068
[TBL] [Abstract][Full Text] [Related]
34. First and second line imatinib treatment in chronic myelogenous leukemia patients expressing rare e1a2 or e19a2 BCR-ABL transcripts.
Andrikovics H; Nahajevszky S; Szilvási A; Bors A; Adám E; Kozma A; Kajtár B; Barta A; Poros A; Tordai A
Hematol Oncol; 2007 Sep; 25(3):143-7. PubMed ID: 17530620
[TBL] [Abstract][Full Text] [Related]
35. Monosomy 7 with severe myelodysplasia developing during imatinib treatment of Philadelphia-positive chronic myeloid leukemia: two cases with a different outcome.
Navarro JT; Feliu E; Grau J; Espinet B; Colomer D; Ribera JM; Oriol A; Granada I; Juncà J; Millá F
Am J Hematol; 2007 Sep; 82(9):849-51. PubMed ID: 17563075
[TBL] [Abstract][Full Text] [Related]
36. [Emergence and decrement of Ph-negative clone with trisomy 8 in CML during imatinib therapy].
Kimura F; Kobayashi S; Ogura K; Kobayashi A; Torikai H; Ikeda T; Sato K; Motoyoshi K
Rinsho Ketsueki; 2004 Sep; 45(9):1058-60. PubMed ID: 15510836
[TBL] [Abstract][Full Text] [Related]
37. Random aneuploidy in CML patients at diagnosis and under imatinib treatment.
Amiel A; Yukla M; Gaber E; Leopold L; Josef G; Fejgin M; Lishner M
Cancer Genet Cytogenet; 2006 Jul; 168(2):120-3. PubMed ID: 16843101
[TBL] [Abstract][Full Text] [Related]
38. Cytogenetic and molecular responses and outcome in chronic myelogenous leukemia: need for new response definitions?
Kantarjian H; O'Brien S; Shan J; Huang X; Garcia-Manero G; Faderl S; Ravandi-Kashani F; Verstovsek S; Beth Rios M; Cortes J
Cancer; 2008 Feb; 112(4):837-45. PubMed ID: 18085610
[TBL] [Abstract][Full Text] [Related]
39. Molecular response to imatinib in patient with Ph negative p190 BCR-ABL transcript positive chronic myeloid leukemia with cyclic leukocytosis.
Radojkovic M; Ristic S; Pavlovic S; Colovic M
Leuk Res; 2009 Jun; 33(6):e10-2. PubMed ID: 19091403
[TBL] [Abstract][Full Text] [Related]
40. Lymphoid transformation in a CML patient in complete cytogenetic remission following treatment with imatinib.
Avery S; Nadal E; Marin D; Olavarria E; Kaeda J; Vulliamy T; Brito Babapulle F; Goldman JM; Apperley JF
Leuk Res; 2004 May; 28 Suppl 1():S75-7. PubMed ID: 15036946
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]